Melanom: A Phase 3, Randomized, Double-Blind Study of Adjuvant Immunotherapy with Nivolumab versus Placebo after Complete Resection of Stage IIB/C Melanoma.

Stadium/Indikation inkl. Kurzinfo

Melanom – Adjuvant
Stadium IIB/C
Anti-PD1 vs Placebo

Kurztitel

BMS CA209-76K
CheckMate 76K
NCT04099251

Offizieller Titel

A Phase 3, Randomized, Double-Blind Study of Adjuvant Immunotherapy with Nivolumab versus Placebo after Complete Resection of Stage IIB/C Melanoma. (CheckMate 76K: CHECKpoint pathway and nivoluMAb clinical Trial Evaluation 76K)